A multidisciplinary approach is needed to evaluate patients suspected of having atypical hemolytic uremic syndrome (aHUS) and to select…
Articles by Joana Carvalho, PhD
The U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application…
In some patients, atypical hemolytic uremic syndrome (aHUS) may be associated with heart disease, a case report study…
Rapid drug desensitization may allow patients with atypical hemolytic uremic syndrome (aHUS) to continue treatment with Soliris (…
Hypertensive emergency and the presence of rare complement mutations are essential to estimate the prognosis of kidney disease in…
Scientists have created a new mouse model for atypical hemolytic uremic syndrome (aHUS) that fully mirrors the clinical symptoms…
Laboratory tests to evaluate the long-term treatment effects of Soliris (eculizumab) on complement inhibition — stopping an overly aggressive…